CClinicalTrials.gg
CompletedNCT03597516Updated Jul 8, 2019

Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

A Phase 3 interventional study of RP-G28 and Placebos in Lactose Intolerance, sponsored by Ritter Pharmaceuticals, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-08.

Sponsored by Ritter Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
557
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US) to assess the efficacy of RP-G28 compared to placebo on symptom reduction related to lactose intolerance.

02

Conditions studied

  • Lactose Intolerance

Browse trials for

Keywords

  • Lactose Intolerance
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient is 18-75 years of age, inclusive, at screening;
  • Intolerance to milk and other dairy products;
  • Patient agrees to refrain from all other treatments and products used for lactose intolerance, to follow diet modifications required during periods of the study that include abstinence from all dairy in some periods and consuming dairy in other periods;
  • Patient meets the defined minimum lactose intolerance symptom composite score; and
  • Patient has positive Hydrogen Breath Test (HBT) results for lactase deficiency.

Exclusion criteria

Exclusion Criteria:

  • Patient has a disorder associated with abnormal gastrointestinal motility such as gastroparesis (from any cause), amyloidosis, neuromuscular diseases (including Parkinson's disease), collagen vascular diseases, uremia, or malnutrition;
  • Patient has undergone bowel preparation for endoscopic or radiologic investigation within 4 weeks of Screening (example, colonoscopy preparation);
  • Patient has a history of surgery that alters the normal function of the gastrointestinal tract including, but not limited to: fundoplication, gastrointestinal bypass surgery, bariatric surgery, gastric banding, colostomy, vagotomy, pyloroplasty, colectomy or other surgery for Crohn's disease or ulcerative colitis; and
  • Patient has received antibiotic treatment, or had a high colonic enema, colonic irrigation, colonic hydrotherapy, or colonic cleaning within 30 days prior to or during Screening.
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
557 participants (actual)

Study arms

  • Experimental
    RP-G28

    galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day

    Drug: RP-G28

  • Placebo comparator
    Placebos

    maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day

    Drug: Placebos

Interventions

  • DrugRP-G28

    powder for reconstitution for oral administration

  • DrugPlacebos

    powder for reconstitution for oral administration

05

What researchers measure

Primary outcomes

  1. Change from baseline of the Lactose Intolerance (LI) symptom composite score compared to placebo

    Change from baseline of the LI symptom composite score compared to placebo. The LI symptom composite score includes abdominal pain, abdominal bloating, abdominal cramping, and abdominal gas.

    Time frame: Day 61

Secondary outcomes

  1. Proportion of patients with a meaningful reduction in LI composite score.

    Proportion of patients with a meaningful reduction in LI composite score. The LI symptom composite score includes abdominal pain, abdominal bloating, abdominal cramping, and abdominal gas.

    Time frame: Day 61

06

Study locations

35 sites
  • Research Facility
    Birmingham, Alabama 35205, United States
  • Research Site
    Chula Vista, California 91910, United States
  • Research Site
    Huntington Park, California 90255, United States
  • Research Site
    Lincoln, California 95648, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    Panorama City, California 91402, United States
  • Research Site
    San Diego, California 92114, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Colorado Springs, Colorado 80906, United States
  • Research Site
    Gainesville, Florida 32653, United States
  • Research Facility
    Miami, Florida 33135, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Reseaarch Site
    Pompano Beach, Florida 33060, United States
  • Research Site
    Honolulu, Hawaii 96815, United States
  • Research Site
    Marrero, Louisiana 70072, United States
  • Research Site
    Oxon Hill, Maryland 20745, United States
  • Research Site
    Wyoming, Michigan 49519, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Berlin, New Jersey 08009, United States
  • Research Site
    Albuquerque, New Mexico 87102, United States
  • Research Site
    Brooklyn, New York 11230, United States
  • Research Site
    Great Neck, New York 11023, United States
  • Research Site
    Hartsdale, New York 10530, United States
  • Research Site
    Raleigh, North Carolina 27612, United States
  • Research Site
    Cincinnati, Ohio 45246, United States
  • Research Site
    Dayton, Ohio 45439, United States
  • Research Site
    Charleston, South Carolina 29406, United States
  • Research Site
    Knoxville, Tennessee 37909, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    Lampasas, Texas 76550, United States
  • Research Site
    San Antonio, Texas 78209, United States
  • Research Site
    Waxahachie, Texas 75165, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Bellevue, Washington 98004, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03597516
Lead sponsor
Ritter Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jul 24, 2018
Start date
Jun 26, 2018
Primary completion
Jul 2, 2019
Completion
Jul 2, 2019
Last update
Jul 8, 2019

Study contacts

Sharron Gargosky, PhD
study director · Ritter Pharmceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion